Businessweek Archives

Table: Mapping The Genome Companies

Cover Story

TABLE: Mapping the Genome Companies

Pharmaceutical giants and biotech startups are mining the treasures in the

human genome. Some key players:


HUMAN GENOME Sequencing almost all human genes, then hopes to

SCIENCES develop drugs and diagnostics, mostly with partners.

SMITHKLINE Invested $125 million in HGS to use its sequences to

BEECHAM create new products.

INCYTE Sequencing cDNA from many different tissues to find

PHARMACEUTICAL interesting genes. Is selling access to its data.

PFIZER Paid InCyte $25 million for access to database.

UPJOHN Signed $20 million deal with InCyte for gene data.

BRISTOL-MYERS Invested in SEQ and Cadus to develop new

SQUIBB sequencing technology and drug screens.

MILLENNIUM Searching for specific genes that cause obesity,

diabetes, asthma, atherosclerosis, and cancer.

HOFFMANN- Signed $70 million deal with Millennium.


MERCK Paid Washington University to sequence

200,000 gene fragments. Makes data public.

SEQUANA Searches family histories and HMO data for genes

THERAPEUTICS that cause hypertension, asthma, and obesity.

AMGEN Sequencing genes to find new drug targets.

TAKEDA Uses SmithKline and HGS data to develop drugs.


Coke's Big Fat Problem

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

blog comments powered by Disqus